This Glasgow Biotech Just Raised $46M to Tackle a Silent Kidney Threat

Jan de Vries · 2026-08-07

A quiet but significant move just happened in the biotech world, and it could change how we treat one of the most common hereditary diseases you've probably never heard of. Mironid, a Glasgow-based biopharmaceutical company, has closed a $46 million Series B financing round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. That's a serious vote of confidence. The round was led by the Scottish National Investment Bank, with a syndicate of existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When that caliber of investor doubles down, it's worth paying attention. ### Why This Matters for Millions of People ADPKD isn't just another rare disease. It's the most common hereditary kidney disorder, affecting over 12 million people worldwide. The numbers are stark: 50% of patients develop kidney failure by age 60. Neil Wilkie, CEO of Mironid, put it plainly: "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD." The company's lead candidate targets the root cause of the disease. ADPKD is caused by mutations in the PKD1 or PKD2 gene, which leads to the uncontrolled growth of fluid-filled cysts in the kidneys. Over time, those cysts crowd out healthy tissue, and in many cases, the kidneys simply fail. That's where Mironid's approach gets interesting. ### A Different Kind of Approach Mironid's LoAc molecules are designed to directly target cyclic AMP (cAMP), a cellular signal that drives both cell proliferation and fluid secretion within the cysts. The company says this signal is active across all stages of the disease, from initiation to end-stage. That's a big deal because most existing therapies only address symptoms, not the underlying mechanism. Preclinical data has shown significant efficacy and a favorable safety profile. We're talking about reductions in cyst number and kidney volume. The idea is to prevent new cyst formation and arrest the growth of existing ones. If that holds up in human trials, it could offer a more durable treatment option with a better side-effect profile than what's currently available. ### The Backstory and the Road Ahead Mironid was spun out of the University of Strathclyde and Heriot-Watt University in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. The company is headquartered in Glasgow and focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory diseases and cancer. Beyond ADPKD, the pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways implicated in disease progression. The company operates on a research-and-development-led model, funded through venture capital and strategic investment. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up well: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." ### What the Money Will Do Proceeds from this Series B will go toward advancing the clinical development of Mironid's first-in-class LoAc small molecule candidate for ADPKD patients. The fresh capital follows an earlier Series A extension round that brought the company's total funding since inception to roughly $47 million. Here's what this funding means in practical terms: - **Clinical trials**: Moving the lead candidate through the necessary phases to prove safety and efficacy in humans. - **Team expansion**: Bringing in the talent needed to execute on the development plan. - **Pipeline progress**: Advancing the PDE4 programs that could eventually address other diseases. The road from preclinical data to approved therapy is long and fraught with risk. But with this kind of backing and a mechanism that targets the disease at its source, Mironid is positioning itself as a serious player in the rare kidney disease space. For the 12 million people affected by ADPKD, that's a glimmer of hope worth watching.